Edgar Petru
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Edgar Petru has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
C. Marth
Medizinische Universität Innsbruck
2 shared publicationsA. Huell
1 shared publicationA. Reinthaller
1 shared publicationA. Stempfl
1 shared publicationA.G. Zeimet
1 shared publicationAngelika Lanz-Veit
Medical University of Graz
1 shared publication
Latest Publications
- 31 October 2008
- Published by Elsevier in Gynecologic Oncology
- Vol. 111 (1) , 159-160
Re: Chemotherapy-related myelosuppression as a marker for survival in epithelial ovarian cancer patients by Rocconi et al.
- 31 October 2008
- Published by Elsevier in Gynecologic Oncology
- Vol. 111 (1) , 159-160
Re: Chemotherapy-related myelosuppression as a marker for survival in epithelial ovarian cancer patients by Rocconi et al.
- 29 October 2008
- Published by Springer Nature in Der Onkologe
- Vol. 14 (11) , 1130-1139
Frühes Ovarialkarzinom (FIGO Stadium I–IIA)
- 29 October 2008
- Published by Springer Nature in Der Onkologe
- Vol. 14 (11) , 1130-1139
Frühes Ovarialkarzinom (FIGO Stadium I–IIA)
- 1 March 2008
- Published by Springer Nature in Wiener Medizinische Wochenschrift
- Vol. 158 (5-6) , 169-173
Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy
Palonosetron is a new generation 5-HT3-receptor antagonist with a significantly prolonged half-life and a once-a-day administration compared to the conventional setrons. To evaluate the antiemetic efficacy of palonosetron in the daily hospital practice setting, a postmarketing study was carried out in Austria.Palonosetron was administered at 0.25 mg on day 1 of each cycle to 135 cancer patients who received moderately or highly emetogenic chemotherapy either as an IV bolus or as a short-term infusion. Two thirds of these patients were females (n = 90), the majority had breast cancer (n = 38) and the majority received cisplatin, carboplatin, anthracyclines, 5-fluorouracil or cyclophosphamide.The complete antiemetic response rate was 68 % overall with 87 % efficacy on day 1 and 72 % efficacy on days 2 to 5. Higher antiemetic response was achieved in male patients, in patients being aged > or = 50 years, and in chemonaive patients. Twenty-four percent of patients needed rescue medication. Only 1.5 % of patients reported mild adverse events.Palonosetron resulted in high antiemetic efficacy in this study. Female gender and age < or = 50 years should be particularly considered when the antiemetic regimen is selected.
- 1 March 2008
- Published by Springer Nature in Wiener Medizinische Wochenschrift
- Vol. 158 (5-6) , 169-173
Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy
Palonosetron is a new generation 5-HT3-receptor antagonist with a significantly prolonged half-life and a once-a-day administration compared to the conventional setrons. To evaluate the antiemetic efficacy of palonosetron in the daily hospital practice setting, a postmarketing study was carried out in Austria.Palonosetron was administered at 0.25 mg on day 1 of each cycle to 135 cancer patients who received moderately or highly emetogenic chemotherapy either as an IV bolus or as a short-term infusion. Two thirds of these patients were females (n = 90), the majority had breast cancer (n = 38) and the majority received cisplatin, carboplatin, anthracyclines, 5-fluorouracil or cyclophosphamide.The complete antiemetic response rate was 68 % overall with 87 % efficacy on day 1 and 72 % efficacy on days 2 to 5. Higher antiemetic response was achieved in male patients, in patients being aged > or = 50 years, and in chemonaive patients. Twenty-four percent of patients needed rescue medication. Only 1.5 % of patients reported mild adverse events.Palonosetron resulted in high antiemetic efficacy in this study. Female gender and age < or = 50 years should be particularly considered when the antiemetic regimen is selected.
- 1 August 2006
- Published by Elsevier in Gynecologic Oncology
- Vol. 102 (2) , 226-229
Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum–taxane therapy: A phase II Austrian AGO study
- 1 August 2006
- Published by Elsevier in Gynecologic Oncology
- Vol. 102 (2) , 226-229
Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum–taxane therapy: A phase II Austrian AGO study
- 1 July 2006
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 5 (7) , 777-8
Regulation of the E2F family: a further step in understanding ovarian cancer biology.
Commentary to: Heterogeneous Cross-talk of E2F Family Members is Crucially Involved in Growth Modulatory Effects of Interferon-? and EGF Daniel Reimer, Susann Sadr, Annemarie Wiedemair, Nicole Concin, Gerda Hofstetter, Christian Marth and Alain G. Zeimet
- 1 July 2006
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 5 (7) , 777-8
Regulation of the E2F family: a further step in understanding ovarian cancer biology.
Commentary to: Heterogeneous Cross-talk of E2F Family Members is Crucially Involved in Growth Modulatory Effects of Interferon-? and EGF Daniel Reimer, Susann Sadr, Annemarie Wiedemair, Nicole Concin, Gerda Hofstetter, Christian Marth and Alain G. Zeimet